Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

Sarepta is facing a shareholder lawsuit over ELEVIDYS-related deaths. Robbins LLP cites safety risks and stock losses.

If you purchased or acquired securities in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your ...

Subscriber Savings deals on local and national brands. PLUS the E-Edition replica of the printed newspaper.

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

Market Growth Driven by Increasing Drug Approvals, Advanced Technologies, Rising Chronic Disease Incidence, and Expanding Therapeutic Applica ...

Sarepta Therapeutics Non-GAAP EPS of -$3.42 misses by $2.77, revenue of $744.9M beats by $60.78M SA NewsTue, May 06 11 Comments ...

Duchenne Muscular Dystrophy Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook ...

The broad market index gained 0.47% and closed at 6,227.42. The S&P 500 scored a fresh all-time intraday high and closed at a ...